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Cilia have important roles in cell/developmental biology but little is known 18 
about what prevents cilia being made at the wrong time. We show that 19 
BCAP is an important inhibitor of ciliogenesis. 20 
 21 
Abstract 22 
The centrosome and cilium are organelles with important roles in 23 
microtubule organisation, cell division, cell signalling, embryogenesis, and 24 
tissue homeostasis. The two organelles are mutually exclusive. The 25 
centriole/basal body is found at the core of the centrosome (centriole) or at 26 
the base of the cilium (basal body) and changing which organelle is present 27 
in a cell requires modification to the centriole/basal body both in terms of 28 
composition and sub-cellular localisation. While many protein components 29 
required for centrosome and cilium biogenesis have been described, there 30 
are far fewer known inhibitors of ciliogenesis. Here we show that a protein 31 
called BCAP and labelled in the sequence databases as ODF2-like (ODF2L) 32 
is a ciliation inhibitor. We show that it is a centriolar satellite protein. 33 
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Furthermore, our data suggest BCAP exists as two isoforms with subtly 34 
different roles in inhibition of ciliogenesis. Both are required to prevent 35 
ciliogenesis and one additionally controls cilium length after ciliogenesis has 36 
completed.  37 
  38 
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 39 
Introduction 40 
 41 
Cilia are hair-like structures found on the surface of many cell types and 42 
have important roles in cell signalling and embryogenesis (Nigg and Raff, 43 
2009). Cilium defects cause inherited diseases (Badano et al., 2006), 44 
polycystic kidney disease being the most prevalent (Ong and Wheatley, 45 
2003). Knowledge of the roles and component parts of the cilium has greatly 46 
expanded in the last decade. However, control of when a cell makes a cilium 47 
is still poorly understood. 48 
The cilium acts a ‘mast’ or antenna for many signalling pathways, 49 
including hedgehog signalling (Huangfu et al., 2003). Mutations in various 50 
cilium components give rise to a large number of individually mainly rare 51 
diseases that are grouped together as the ciliopathies (Badano et al., 2006), 52 
including Meckel-Grubel, Alstrom, Joubert and Bardet-Biedl syndromes 53 
(Ansley et al., 2003; Collin et al., 2002; Dawe et al., 2007). These diseases 54 
affect multiple tissues and symptoms include retinal degeneration, 55 
polydactyly, kidney cysts and neurological features, reflecting the multiple 56 
roles of cilia in cellular communication, cellular functioning and 57 
developmental biology. 58 
The internal frame or superstructure of the cilium is composed of an 59 
axoneme of nine microtubule doublets, cylindrically arranged (Satir and 60 
Christensen, 2007). At the base of this is another microtubule-based 61 
structure, the barrel-shaped basal body. This closely resembles the 62 
centrioles found in the centrosome, the major microtubule nucleating centre 63 
of animal cells and component of the two poles of the mitotic spindle 64 
(Bornens, 2002; Doxsey, 2001; Tassin and Bornens, 1999). Indeed, cells use 65 
a centriole to make the basal body and do so when they leave the cell cycle, 66 
either temporarily or when they differentiate into specialised cell types (Nigg 67 
and Raff, 2009). 68 
The sequence of changes from centriole to basal body was first 69 
visualised by Sorokin using electron microscopy (Sorokin, 1962). One of the 70 
two centrioles, the mother centriole, which has additional, bracket-like 71 
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appendage structures at its distal end, acquires a vesicle-like structure at 72 
this end and migrates to the cell surface. There the membranes fuse. The 73 
basal body is tightly bound to the membrane and transition zone fibres form 74 
between the two. The axoneme is templated from the basal body and 75 
extends, covered in membrane, away from the basal body. 76 
The switch between centriole and basal body, centrosome and cilium 77 
is tightly regulated. Autophagy is used to remove molecules that otherwise 78 
inhibit ciliogenesis (Pampliega et al., 2013; Tang et al., 2013). Few negative 79 
regulators or inhibitors of ciliogenesis are known (Kim et al., 2010). Some 80 
are components of regulatory networks that affect processes in addition to 81 
ciliogenesis (Kim et al., 2010; Kasahara et al., 2014). Others, such as OFD1 82 
and CP110, are centrosome components (Tang et al., 2013; Tsang et al., 83 
2008). CP110 acts through Rab8 and Cep290 to inhibit ciliogenesis (Tsang 84 
et al., 2008). It also functions to prevent microtubules extending from the 85 
distal end of the centriole/basal body (Schmidt et al., 2009). It therefore also 86 
has a role in regulating centriole and centrosome duplication during S phase 87 
of the cell cycle, when two new centrioles bud from a template assembled on 88 
the side of the two existing centrioles and gradually extend until they reach 89 
full length in early G2. OFD1 similarly is involved in regulating centriolar 90 
length and is also involved in distal appendage formation (Singla et al., 91 
2010) 92 
The centrosome components that are known to be negative regulators 93 
of ciliogenesis also have other roles in centrosome biology and 94 
centrosome/centriole duplication during the cell cycle. This, together with 95 
the necessarily tight control of whether a cell has a cilium versus a 96 
centrosome, suggests that dedicated, centrosome-localised inhibitors of 97 
ciliogenesis should exist. Here we report that BCAP is a negative regulator or 98 
inhibitor of ciliogenesis that needs to be removed for cilia to be made. 99 
BCAP was first discovered by Ponsard and colleagues (Ponsard et al., 100 
2007) but has since been annotated in the sequence databases as ODF2L or 101 
ODF2-like due to homology (28% identity, 51% similarity) to ODF2, a 102 
centriolar appendage protein (Lange and Gull, 1995; Nakagawa et al., 2001). 103 
Ponsard et al. found this protein to be expressed mainly in tissues 104 
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containing motile cilia, where its expression increased as cells differentiated 105 
and ciliated. Five isoforms were described, three long isoforms of about 65 106 
kDa, and two short isoforms at 40 kDa. Ponsard et al. decribed BCAP as 107 
localising to basal bodies in ciliated cells and the centrioles of proliferating 108 
cells. Although there is similarity at the sequence level to ODF2, they 109 
observed that BCAP occupied a distinct zone within the centrosome. 110 
We report here that BCAP is also a centriolar satellite protein. We 111 
detect two isoforms in our cell lines. Both inhibit ciliogenesis but appear to 112 
have subtly different roles in this process. 113 
 114 
Results 115 
BCAP/ODF2L/ODF2-like is a centriolar satellite protein 116 
We previously have investigated the role of centrosome proteins in 117 
neural progenitor divisions in the zebrafish retina (Novorol et al., 2013). One 118 
protein we depleted from zebrafish embryos was ODF2, a component of the 119 
appendages of the mother centriole (Lange and Gull, 1995). Depleting this 120 
protein was not embryonic lethal but did result in various defects, including 121 
smaller eyes and brain. Since the sequence databases of mammalian species 122 
contain a sequence annotated as a related protein, ODF2-like or ODF2L, we 123 
sought to characterise this protein to see if it could be acting redundantly 124 
with ODF2. It has previously been named as BCAP (Basal body, centriole 125 
associated protein), with localisation at the basal bodies of multi-ciliated 126 
tracheal cells described (Ponsard et al., 2007). 127 
We first tested the localisation of BCAP within human cell lines using 128 
the few commercially available antibodies and found one that gave staining 129 
near the centrosome, Biorbyt orb31049 (which we will refer to as the anti-130 
BCAP (Biorbyt) antibody) . We expected to see localisation at one of the two 131 
centrioles only, as the centriolar appendages, of which ODF2 is part, are 132 
present on the mother but not daughter centriole (Lange and Gull, 1995; 133 
Mogensen et al., 2000; Nakagawa et al., 2001). Instead, we observed a 134 
speckled staining of numerous small punctae forming a cloud around the 135 
centrioles of the centrosome, visualized by staining for gamma tubulin (Fig. 136 
1A-C,I). 137 
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To confirm the specificity of the staining of the anti-BCAP (Biorbyt) 138 
antibody we decided to test if it would bind to GFP-BCAP expressed in cells. 139 
HeLa cells were transfected with a plasmid encoding GFP-BCAP and then 140 
stained with anti-gamma tubulin or anti-BCAP (Biorbyt) antibody. GFP-141 
BCAP was strongly stained by the anti-BCAP (Biorbyt) antibody we were 142 
using (Fig. 1D-F) with staining overlapping with green fluorescence from 143 
GFP-BCAP. The green fluorescence from GFP-BCAP was punctate in nature 144 
and present as a cloud around the centrosome (Fig. 1G). 145 
This staining pattern is characteristic of centriolar satellites 146 
(Tollenaere et al., 2015), protein dense structures that are involved in 147 
transport to and from the centrosome. The prototypical centriolar satellite 148 
protein is PCM-1 (Balczon et al., 1994; Kubo et al., 1999) whose staining 149 
(Fig. 1H) resembles that of BCAP. We therefore tested if the localisation of 150 
BCAP coincided with that of PCM-1 by staining human cell lines transfected 151 
with GFP-BCAP with anti-PCM-1 antibody. There was nearly full overlap 152 
between the signals (Fig. 1J-L). This is consistent with BCAP being a 153 
centriolar satellite protein.  154 
The structure of satellites and the localisation of many other proteins 155 
to these structures depends on the presence of PCM-1(Stowe et al., 2012). 156 
When we depleted PCM-1 by RNAi, the localisation of the BCAP signal 157 
changed. There was no centriolar satellite staining but instead a diffuse and 158 
non-punctate cytoplasmic staining was observed (Fig. 1M-O). This is again 159 
consistent with BCAP being a centriolar satellite protein. 160 
Since some proteins have multiple localisations within the cell or 161 
within a particular organelle, such as OFD1 at the centriolar appendages 162 
and in the centriolar satellites (Ferrante et al., 2009; Singla et al., 2010; 163 
Tang et al., 2013), we carefully examined the localisation of BCAP in 164 
multiple cells. In many cells, we could observe BCAP staining around but 165 
not overlapping with that of gamma tubulin, which stains the material 166 
immediately around the centrioles (Fig. 1I).  167 
Since BCAP has a different localisation from ODF2, we re-examined 168 
the homology between BCAP and ODF2. The two proteins only share 51% 169 
amino-acid sequence similarity and 28% identity, in a region comprising 170 
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less than half of the protein length. We then explored the relationship 171 
between ODF2 and BCAP by constructing a phylogentic tree (Fig. 2A). We 172 
compared BCAP and ODF2 sequences from animals representative of 173 
amphibians (Xenopus tropicalis), reptiles (Anolis carolinensis), birds (chicken, 174 
Gallus gallus), rodents (domestic mouse, Mus musculus) alongside the 175 
human sequences. All BCAP sequences grouped together, separate from the 176 
group of ODF2 sequences. There is a clear split between BCAP and ODF2 177 
groups implying they diverged at the latest in the last common ancestor for 178 
terrestrial vertebrate animals. ODF2L/ODF2-like is therefore a potentially 179 
misleading name for BCAP. We will continue to use the name BCAP, as first 180 
proposed by Ponsard et al. to refer to this protein from now on. The 181 
relationship between the different isoforms of BCAP, those described by 182 
Ponsard et al. and those predicted in the NCBI database, is shown in Figure 183 
2B, together with the binding sites of the antibodies and siRNAs used in this 184 
study, as described below. 185 
 186 
The role of BCAP in ciliogenesis 187 
Centriolar satellites are important for ciliogenesis and the localisation 188 
of component proteins changes during this process (Kubo et al., 1999; 189 
Stowe et al., 2012). We therefore tested the localisation of BCAP in RPE1-190 
hTERT cells that had been induced to ciliate by serum starvation (Fig. 3).  191 
The anti-BCAP (Biorbyt) antibody showed clear satellite staining in RPE1-192 
hTERT in serum-supplemented, proliferating conditions (Fig. 3A). However, 193 
this antibody did not stain the region around the centrioles/basal bodies in 194 
serum-starved RPE1-hTERT cells, implying that BCAP had disappeared 195 
during ciliogenesis (Fig. 3B). Whether this was by degradation or dispersal 196 
could not be determined by immunofluorescence alone. Overexpressing 197 
GFP-BCAP gave a surprising result. Staining was observed around the 198 
centrioles/basal bodies with the expected pattern but we did not observe in 199 
serum free media any transfected cells with cilia, as visualised by staining 200 
with anti-acetylated tubulin (Fig 3C,D,E). This suggested that BCAP can act 201 
to suppress the formation of cilia. 202 
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We assayed how expression levels of BCAP differed before and after 203 
ciliation. Western blotting of extracts of RPE1-hTERT and HeLa cells with 204 
the anti-BCAP (Biorbyt) antibody under serum-supplemented (non-ciliating) 205 
and serum-free (ciliating) conditions showed that BCAP was readily 206 
detectable in serum-supplemented conditions but absent when cells had 207 
ciliated (Fig. 3F,G). This suggests that during ciliogenesis existing BCAP is 208 
not dispersed from the centriolar satellites but removed from the cell.  209 
If BCAP normally acts as a ciliogenesis inhibitor, then depleting BCAP 210 
might allow for cilia to be made under conditions in which cells normally 211 
maintain a centrosome. We depleted all isoforms of BCAP by RNAi (two 212 
separate siRNAs, locations of target sites shown in Fig. 2B). Depletion was 213 
confirmed by RT-PCR (Fig. 4A,B) and immunocytochemistry (Fig. 4C). When 214 
RPE1-hTERT cells were transfected with these siRNAs in serum-215 
supplemented media, conditions under which they normally do not ciliate, 216 
cilia were now extensively generated (Fig. 4E,F). Cilium length was also 217 
increased by a quarter, from 3.1 µm to 4.1 µm (p<0.001 by ANOVA, both 218 
siRNAs) (Fig. 4G-I). This knockdown could be rescued by overexpressing 219 
mouse BCAP, whose coding sequence is not completely identical to human 220 
BCAP at the target sites of the two siRNAs used. When cells were depleted of 221 
BCAP by siRNA transfection while simultaneously transfected with an 222 
expression construct for mouse BCAP, no cilia were formed (Fig. 4K-N). 223 
Together, these overexpression and/or depletion experiments are consistent 224 
with BCAP acting as a ciliogenesis inhibitor. 225 
Depletion of BCAP did not alter the pattern of staining of ODF2, 226 
gamma tubulin or PCM-1 (Fig. 4O-Q).  Centriolar satellite and centrosome 227 
structure would therefore appear not to be grossly affected by BCAP 228 
depletion as these markers for the satellites, pericentriolar matrix and 229 
appendages showed normal localisation when BCAP was absent. 230 
 231 
BCAP has multiple isoforms, two of which are present in RPE-232 
hTERT cells 233 
 234 
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When we repeated these experiments with a different anti-BCAP 235 
antibody, 23887-1-AP from Proteintech (anti-BCAP (Proteintech) antibody), 236 
we obtained slightly different results. Proliferating cells still showed a 237 
satellite pattern of staining (Fig. 5A-C), but, by Western blotting, BCAP 238 
remained present though at reduced levels after ciliogenesis had completed 239 
(30% reduction, Fig. 5D,E). By immunofluorescence, in a mixed population 240 
of RPE1-hTERT cells at different stages of ciliogenesis, a portion of cells had 241 
an absence of staining and some showed satellite staining around the basal 242 
bodies (Fig. 5F-H). This staining overlapped with that of PCM-1 (Fig 5I) and 243 
partially overlapped with that of gamma-tubulin (Fig. 5J), in that centrioles 244 
as well as satellites were stained. Notably, the staining pattern was not 245 
restricted to one centriole like ODF2 (Fig  5K). 246 
We sought to image how BCAP localization, as visualised by the anti-247 
BCAP (Proteintech) antibody, changes during ciliogenesis. We synchronised 248 
cells with a nocodazole block, then released them into medium lacking 249 
serum and fixed samples every hour. These samples were then stained with 250 
the anti-BCAP (Proteintech) antibody (Fig. 6A) and acetylated tubulin 251 
antibody.  252 
BCAP staining changed during the course of ciliogenesis. Immediately 253 
after release from the nocodoazole block, BCAP staining showed a scattered 254 
pattern (Fig. 6A). BCAP then adopted a more satellite-like appearance within 255 
an hour. As ciliogenesis started, all BCAP staining disappeared, with 256 
negligible fluorescence signal (Fig. 6B). As ciliogenesis neared completion at 257 
8h (Fig. 6C), BCAP staining was then again observed in the centriolar 258 
satellites (Fig. 6A) with BCAP returning to 50% of pre-ciliogenesis levels (Fig 259 
6B). 260 
The different results from the two anti-BCAP antibodies used could be 261 
explained by the existence of multiple isoforms of BCAP. ENSEMBL and 262 
NCBI databases predict several splice variants of BCAP based on genomic 263 
and EST data (Fig 2B), and Ponsard et al. (2007) describe five isoforms. We 264 
have combined these data in Figure 2B, using Greek letters to label the 265 
combined set, but also showing the names used by Ponsard et al. and the 266 
NCBI database, on the right-hand side of the figure,. There are five long 267 
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isoforms, all of similar size, which vary by the inclusion of exons 2, 10, 13 268 
and 14, plus two short isoforms that include exon 10 but differ by the 269 
presence/absence of exons 13 and 14.  270 
We tested RPE-hTERT cells for the presence of these isoforms by RT-271 
PCR. With the primer pair used to test for inclusion/skipping of exon 10, we 272 
observed only the smaller band produced if exon 10 was skipped (Fig 7A). 273 
This is consistent with the short isoforms and two of the long isoforms being 274 
absent, isoforms β, γ, ζ, η. For exon 13, we observed both larger and smaller 275 
bands which would be produced if this exon was either included or skipped 276 
in different isoforms. These data are consistent with the presence of the 277 
α, δ and ε isoforms (Fig. 2B). When we cloned and sequenced BCAPδ/ε, we 278 
observed only the δ isoform (Fig. 7B), and similarly, we observed only one 279 
band when amplifying BCAPα. In our cells, it would appear that only the α 280 
and δ isoforms are present. Compared to BCAPα, in BCAPδ exon 13 is 281 
skipped but exon 19 substitutes for the very short exon 18 that is 282 
incorporated in BCAPα. BCAPα and δ will therefore have almost identical 283 
molecular masses of 69kDa. 284 
The anti-BCAP (Biorbyt) antibody was raised to the C-terminus of 285 
BCAPα whereas the anti-BCAP (Proteintech) antibody was raised to the 286 
common N-terminus of both α  and δ isoforms (Fig. 2B). The results above 287 
suggest that in RPE-hTERT cells two isoforms of BCAP exist with slightly 288 
different expression patterns. BCAPα is completely removed in ciliated cells. 289 
BCAPδ returns to cells that have made cilia. 290 
 To further refine the roles of the two variants, we cloned the human 291 
BCAPα and BCAPδ. GFP-BCAPα showed centriolar satellite staining and no 292 
centriolar staining (Fig 7C-K) consistent with the antibody staining. In 293 
contrast, GFP-BCAPδ showed centriolar and satellite staining (Fig 7L-Q). The 294 
antibody to all isoforms (α to η) of BCAP, raised by Ponsard et al. (2007), 295 
stained centrosomes, centrioles and basal bodies in human nasal epithelial 296 
(HNE) cells.  297 
We depleted each isoform separately. By RT-PCR, depletion was 89% 298 
and 80% respectively for BCAPα and BCAPδ (Fig. 8A,B). In both cases, the 299 
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anti-BCAP (Proteintech) antibody staining decreased but was not eliminated, 300 
consistent with it binding both isoforms (Fig 8 C-E). Depletion of either 301 
protein using a variant-specific siRNA resulted in ciliogenesis occurring in 302 
serum-supplemented conditions. 30% of cells now formed cilia when either 303 
BCAPα or BCAPδ was depleted alone, compared to 70% when both isoforms 304 
were depleted together (Fig 8F). This is consistent with the two isoforms 305 
acting together to suppress ciliation.  306 
When either BCAPα or BCAPδ were depleted from cells undergoing 307 
serum starvation, cilia were formed as expected but it was notable that 308 
cilium length increased in BCAPδ depleted cells but not in those depleted of 309 
BCAPα (Fig 8G-J). 310 
Overexpression of either GFP-BCAPα or GFP-BCAPδ suppressed 311 
cilium formation in serum-free media, consistent with our previous 312 
observations (Fig 8K-P). The proportion of cells with cilia decreased from 313 
80% to 25% in both cases (Fig 8Q). There appears to be partial redundancy 314 
in the roles of BCAPα and BCAPδ since overexpressing BCAPα in cells 315 
depleted of BCAPδ suppresses ciliation and the reciprocal experiment yields 316 
the same result (Fig. 8R-X). 317 
These data suggest that BCAP exists as two isoforms in RPE1-hTERT 318 
cells. Both isoforms are removed during ciliogenesis but one, BCAPδ, 319 
reappears once ciliogenesis has completed. Both suppress ciliation but 320 
additionally BCAPδ acts to control cilium length once cilia have formed. 321 
 322 
BCAP depletion does not affect a role in microtubule regrowth 323 
and reorganization nor the cell cycle 324 
 325 
Since other ciliogenesis inhibitors, OFD1 and CP110 have additional 326 
centrosome/centiole-based functions (Schmidt et al., 2009; Singla et al., 327 
2010), we assayed BCAP for other roles at the centrosome. We first tested if 328 
BCAP had a role in microtubule nucleation, a major role of the centrosome 329 
in interphase cells (Bornens, 2002; Tassin and Bornens, 1999), using the 330 
microtubule regrowth assay (Fry et al., 1998). BCAP-depleted cells (both 331 
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isoforms; siRNA1) showed no detectable difference in the time at which 332 
microtubule nucleation restarted or the rate at which the network was re-333 
established, compared to control treated cells (Fig. S1A-J). BCAPα and δ are 334 
therefore not required for microtubule nucleation. At the zero time-point, the 335 
microtubule network in BCAP-depleted cells appeared similar to that of 336 
control cells so the mature microtubule network seems unaffected by 337 
removal of BCAPα/δ. 338 
We also tested whether BCAP is required for adjusting an existing 339 
microtubule network. We used the wound assay on confluent RPE1-hTERT 340 
cells to test if BCAP (either isoform) had a role in cell migration and polarity 341 
through the centrosome (Nobes and Hall, 1999)(Luxton and Gundersen, 342 
2011). In both control and siRNA-transfected cells, the wound closed at the 343 
same rate (Fig. S1K-P). Staining the cells for Golgin-97 and gamma tubulin 344 
showed that both BCAP-depleted and control cells behaved the same, with 345 
the Golgi apparatus and centrosome reorientating towards the direction of 346 
the wound during closure (Fig. S1Q,R). By this assay, depletion of BCAP 347 
(both isoforms) neither inhibits migration nor adversely affects cell polarity. 348 
 Finally, we tested for a role of BCAP in the cell cycle. The centrosome 349 
contributes to the poles of the mitotic spindle and has a critical role both in 350 
nucleating astral microtubules and facilitating the fast generation of a 351 
mitotic spindle (Basto et al., 2006; Stevens et al., 2007). Furthermore, 352 
depletion of many centrosome proteins results in a G1 arrest, before the 353 
cells commit to entering the cell cycle (Mikule et al. 2007). We found that 354 
BCAP-depleted RPE1-hTERT cells showed the same distribution of cell cycle 355 
phases as control treated cells, after 24 h culture (Fig. S2A,B), including 356 
after first serum-starving the cells for 24 h (Fig. S2C, D). Thus BCAP 357 
depletion (both isoforms) does not cause a G1 block nor does it prevent 358 
progression into mitosis. On balance, the role of BCAP appears to be specific 359 
to the regulation of ciliogenesis.  360 
  361 
Discussion 362 
 363 
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We describe here BCAP as a centriolar satellite protein that acts as an 364 
inhibitor of ciliation, specifically, the initiation of ciliogenesis. 365 
Overexpression of BCAP in cells, under conditions that normally cause cells 366 
to form cilia, prevents this from occurring. Depletion of BCAP under 367 
conditions in which ciliation is not normally observed results in a 368 
substantial portion of cells producing cilia. 369 
Many centrosome proteins, including those in the satellites, have been 370 
shown to contribute to ciliogenesis. Few proteins, centrosomal or otherwise, 371 
have been found to be inhibitors of ciliation. BCAP partially resembles 372 
OFD1, a known inhibitor of ciliogenesis in that depletion of OFD1 modulates 373 
ciliogenesis in the same direction and with the same magnitude as depletion 374 
of BCAP (Tang et al., 2013). Whereas OFD1 has other roles in centrosome 375 
biology, so far we have not been able to determine other roles for BCAP in 376 
centrosome function. BCAPα appears to be present at centriolar satellites 377 
only in cycling cells with BCAPδ at the centrioles in addition; OFD1 is also 378 
present at the appendages (Singla et al., 2010). While super-resolution or 379 
immuno-gold TEM would categorically rule out other localisations, we do not 380 
observe any BCAPα at the centrioles in cycling cells, although we do observe 381 
BCAPδ at both the centrioles in addition to satellite staining.  382 
The antibody raised by Ponsard et al. was designed to detect all BCAP 383 
isoforms, using a mixture of peptide sequences encoded by exons 13 and 15. 384 
Exon 15 is included in all isoforms, although exon 13 is present in only two 385 
of the long isoforms (L-BCAP/α and L-BCAP del 2/ε), and one short isoform 386 
(S-BCAP/η).  Ponsard et al. also used human nasal epithelial (HNE) cells in 387 
an air-liquid interface culture to cause differentiation of the cells into multi-388 
ciliated epithelial cells. Both the peptide against which the antibody was 389 
raised and the nature of the cell line used may contribute to the 390 
centrosome/centriole staining they observe, which resembles the staining 391 
we observe in some cells when GFP-BCAPδ is expressed in RPE-hTERT cells. 392 
Another ciliation inhibitor, CP110, localises to the distal tips of 393 
centrioles to act as a capping protein (Schmidt et al., 2009). In this role, 394 
CP110 can control elongation of the pro-centrioles during centriole 395 
14 
 
duplication in S-phase. BCAPα does not show centriolar localisation but 396 
BCAPδ does to some extent. During ciliogenesis, CP110 acts through Rab8 397 
and Cep290 to control ciliation initiation (Tsang et al., 2008). Cep290 is 398 
another satellite protein. Whether BCAPα and/or δ link CP110 and Cep290 399 
together or inhibit ciliogenesis by a different means would be a logical 400 
avenue for future investigation. 401 
Any explanation of how BCAP controls ciliogenesis also has to 402 
consider the seven possible splice variants predicted by us and others. Our 403 
analysis in RPE-hTERT cells supports the presence of two protein isoforms, 404 
with only one detected by the anti-BCAP (Biorbyt) antibody but both 405 
detected by the Proteintech antibody. The BCAPα variant detected by the 406 
anti-BCAP (Biorbyt) antibody completely dissappears during ciliogenesis, 407 
implying its removal is required for ciliogenesis to initiate, continue and for 408 
cilia to be maintained. The anti-BCAP (Proteintech) antibody shows that 409 
total BCAP, ‘α’ and ‘δ’ variants together, disappears at the start of 410 
ciliogenesis but BCAP returns, albeit at a lower levels, once ciliogenesis is 411 
complete. This can be explained if the ‘δ’ variant also needs to be removed 412 
for ciliogenesis to start and then the ‘δ’ form has another function once cilia 413 
have been made. BCAP α and δ are partially redundant in that both can 414 
suppress ciliation but removal of either one by RNAi only gives half the rate 415 
of ciliation observed when both are removed at the same time. In HNE cells, 416 
which differentiate into multi-ciliated (motile) cells, as opposed to 417 
monociliated (immotile) RPE-hTERT cells, more isoforms may be needed to 418 
ensure this process is properly controlled. An added complication in multi-419 
ciliated cells is the requirement for centriole duplication to generate the 420 
(hundreds of) extra basal bodies, ciliogenesis from which then needs to be 421 
controlled and directed to the correct side of the cell. 422 
We tested several other centrosome functions in BCAP depleted cells 423 
as the siRNAs used for RNAi-mediated depletion target a region shared by 424 
both variants. Depletion of total BCAP, both α and δ variants, did not affect 425 
microtubule regrowth, cell polarity, migration or re-entry into the cell cycle. 426 
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Instead, the function of BCAPδ could be regulation of cilium length. In 427 
cells transfected with siRNA duplexes targetting both BCAP variants, cilium 428 
length is increased. Depletion of BCAPδ also results in an increase in cilium 429 
length but this is not observed when BCAPα is depleted.  BCAPδ may 430 
therefore additionally act as a late inhibitor of ciliogenesis, moderating 431 
cilium length. There are therefore parallels and contrasts to the roles 432 
ascribed in ciliogenesis to autophagy. In this regard it is of note that BCAP 433 
is predicted to have an APG6 domain (region similar to yeast autophagy 434 
protein 6). 435 
Early on after serum starvation and initiation of ciliogenesis, 436 
autophagy is activated and Tang et al. (2013) show that this is needed to 437 
remove OFD1, an inhibitor. Pampliega et al. (2013) further show that 438 
autophagy needs to be directed differently before, during and after 439 
ciliogenesis. Once ciliation has finished, and full-length cilia have been 440 
made, autophagy is directed to limiting cilium length. In this situation, 441 
reduced autophagy results in abnormally long cilia. The latter mirrors the 442 
effect of absence of BCAP in cells in which cilia have been established. 443 
Autophagy and BCAP would therefore both appear to have a role at this 444 
stage in limiting cilium length. Pampliega et al. (2013) propose that in 445 
unciliated cells and those which possess cilia, autophagy is used to limit the 446 
availability of IFT20 which it turn affects Golgi-cilium movement. BCAP 447 
might therefore aid in this process. However, when ciliogenesis initiates, 448 
BCAP needs to be removed. It is not clear then if BCAP is a target of 449 
autophagy, like OFD1, or an aid in the pathway. The presence of two 450 
distinct isoforms may be due to this requirement to have BCAP present 451 
before and after ciliogenesis but not during the process. 452 
BCAP has also been shown to be upregulated in the mouse trachael 453 
cell ciliation model, (Vladar and Stearns, 2007) though the data do not show 454 
which variant (Tim Stearns, personal communication). If BCAPδ is required 455 
to moderate cilium length, then it would be consistent that its expression is 456 
upregulated in cells with hundreds of cilia, as opposed to the one primary 457 
cilium in the cell lines studied here. 458 
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Future work will be to place BCAP within known ciliogenesis 459 
regulatory networks, inhibitory mechanisms and processes that relieve this 460 
repression. Obvious processes to check are the autophagy pathway and 461 
IFT20-mediated control of primary ciliary vesicle formation. The 462 
CP110/Cep97/Cep290 pathway could be checked as well, though the 463 
current localisation data point away from this mechanism. These 464 
hypotheses will form the basis of more extensive future studies. 465 
 466 
Materials and methods 467 
Cell culture 468 
 469 
HeLa cells were provided by Prof. George Dickson’s laboratory at Royal 470 
Holloway. The hTERT-immortalised human retinal pigment epithelial cell 471 
line (RPE1-hTERT, ATCC cat#: CRL-4000) was kindly provided by Prof. 472 
Erich Nigg, Basel, Switzerland. HeLa cells were grown in Dulbecco’s Modified 473 
Eagle’s Medium (Sigma D6546) supplemented with 2 mM L-Glutamine 474 
(Sigma G7513), 10% Foetal Bovine Serum (Gibco 10500-064) and 1% 475 
antibiotic-antimycotic mixture (Gibco 15140-122). hTERT-RPE-1 cells were 476 
grown Dulbecco’s Modified Eagle’s Medium with nutrient mixture F-12 Ham 477 
(Sigma D6421) supplemented with 10% Foetal Bovine Serum, 0.348% 478 
sodium bicarbonate and 1% antibiotic-antimycotic mixture. HuH-7 cells 479 
were cultured in Dulbecco’s Modified Eagle’s Medium (Sigma D6546) 480 
supplemented with 10% Foetal Bovine Serum and 1% antibiotic-antimycotic 481 
mixture. Cells were grown in Corning 25 and 75 cm2 vent-capped flasks and 482 
6-well plates (Nunc, Denmark) and incubated at 37°C with 5% CO2 in a 483 
humidified incubator and confluence was assessed by microscopy. Ethanol-484 
washed coverslips were added to the 6-well plates to enable subsequent 485 
processing for immunofluorescence microscopy. These coverslips were fixed 486 
in methanol at -20°C or 4% (v/v) formaldehyde (FA) for 3-5 min before 487 
antibody incubation. 488 
 489 
Immunocytochemistry.  490 
 491 
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Coverslips were blocked in 1% or 3% BSA in PBS for 30 min at room 492 
temperature. After blocking, coverslips were placed on top of a paraffin film 493 
attached to flat surface. Then 100-200 µL of primary antibody solution was 494 
added to the top of the coverslip. The coverslip were incubated with the 495 
primary antibody for 60-120 min at room temperature or overnight at 4°C. 496 
After the incubation, coverslips were transferred back to a 6-well plate and 497 
washed three times with PBS at room temperature. Then the coverslips were 498 
incubated with the secondary antibodies identically to the procedure 499 
described above and incubated for 60 min at room temperature. After the 500 
incubation, coverslips were transferred back to a 6-well plate and washed 501 
again with PBS three times and then mounted on 10-15  µL of Vectashield 502 
mounting media with DAPI (Vectorlabs, Peteborough, UK) on to glass slides 503 
for microscopy. The mounted coverslips were sealed with nail varnish and 504 
left to dry for 1-2 hours in a dark chamber before microscopy. Primary 505 
antibodies used as follows: mouse acetylated α-tubulin (Sigma-Aldrich, 506 
T7451) 1:500; Mouse anti-γ-Tubulin (Sigma-Aldrich, T6557) 1:2500; mouse 507 
anti-PCM1 1:1000 (CL0206, Sigma); Rabbit anti-γ-Tubulin (Sigma-Aldrich, 508 
T5192) 1:1000; Mouse anti-Golgin-97 (ThermoFisher, Q92805) 1:1000; 509 
Rabbit Anti- BCAP (Biorbyt, orb31049) 1:100; Rabbit anti- BCAP 510 
(Proteintech, 23887-1-AP); and Rabbit Anti-PCM-1 (Sigma,  HPA23374), 511 
1:1000. Secondary antibodies used as follows: Anti-mouse Alexa Fluor 594 512 
(Invitrogen) 1:1000 and anti-rabbit Alexa Fluor 488 1:1000.  513 
Images collected with either Nikon Eclipse TE300 inverted microscope 514 
(Nikon, UK) with 40x Plan Flour objective (Nikon) or 60X Plan Apochromat 515 
oil immersion objective with NA 1.4 standard filter sets (Nikon) attached to 516 
1.3 megapixel ORCA-100 cooled CCD camera (model C4742-95, 517 
Hamamatsu, Japan) and Hamamatsu HCImageLive (Hamamatsu 518 
Corporation, Japan) software or Nikon Eclipse Ni-E microscope (CF160 519 
optical system, Nikon) with 60X Plan Apochromat oil immersion objective 520 
attached to 1.5 megapixel monochrome DS-Qi1MC cooled CCD camera and 521 
NIE Br (Nikon, UK) software. Confocal microscopy stacks were obtained with 522 
the Olympus IX81/FV-1000 laser confocal system with 63X Plan 523 
Apochromat oil immersion objective (Olympus) using Ar gas laser and He-Ne 524 
18 
 
diode laser. Image Z-stacks were analysed using Olympus FV-1000 Fluoview 525 
2.0 C software. 526 
 527 
Molecular cloning and transient transfection of DNA into 528 
Mammalian cells. 529 
 530 
Molecular cloning followed standard protocols (Sambrook and Russell, 531 
2001) and the instructions of the manufacturer of the kits, reagents and 532 
enzymes used.  All restriction enzymes and polymerases were obtained from 533 
Promega (UK). The mouse full length BCAP cDNA I.M.A.G.E clone (cDNA 534 
clone MGC: 28123, IMAGE:3979963, Gene bank accession BC020075.1, 535 
Gene ID 52184) was purchased from Source BioScience (Nottingham, UK). 536 
The mouse cDNA was amplified and 5’ BamH I and 3’ Xho I restriction sites 537 
were added to the cDNA during amplification by PCR using (5’ 538 
ttttggatcctcATGGAGATGCCTACTAGTGATGG 3’ and 5’ 539 
ttttctcgagttagtcgacTCTAAACATCGTTACATAGGAAATTTG 3’). Then a BamH I- 540 
Xho I fragment containing full-length BCAP was inserted into the 541 
pCS2P+EGFPN cut with Xho I and Bgl II. Similarly we cloned hBCAPα and 542 
hBCAPδ using primers 5’ tttgggatcctgATGGAGAAGGCTGTAAATGA 3’ 543 
(Forward primer for both transcripts), 5’ 544 
tttgtcgacTCATGGAGTCTCTGGATCAC 3’ (reverse primer hBCAPα) and 5’ 545 
tttgtcgacTTATTCAAACATTGTTACATAA 3’ (reverse primer hBCAPδ). The PCR 546 
product was cut with BamH I- Sal1, and inserted into pCS2P+EGFPN cut 547 
with Sal1- Bgl II. 548 
HeLa and RPE1-hTERT cells were transiently transfected with DNA 549 
constructs for expression using Lipofectamine 2000 (Life Technologies) 550 
according to the manufacturer’s protocols. For all the transfections in 6-well 551 
format, 2.5 – 3 µg of plasmid DNA was used and diluted in 250 µL Opti-552 
MEM. Both, Lipofactamine 2000 and DNA mixtures were incubated for 5-10 553 
min at room temperature before combining together and then addeing to 554 
each well and incubating for 5-6 h (37°C with 5% CO2) before replacing with 555 
serum supplemented, antibiotic free medium and incubating for 24-48h. 556 
 557 
19 
 
RNA interference  558 
 559 
The siRNAs were designed with custom RNA synthesis tools 560 
(siDESIGN Center) provided by GE Dharmacon to BCAP transcripts: 561 
XM_005271056, NM_001184766, NM_020729, XM_005271057, 562 
NM_001184765, NM_001007022, XM_005271055, XM_005271054. The 563 
siRNA oligo sequences were designed to have overlap of 19 nucleotides and 564 
2 nucleotide overhangs on both 3’-end of the sense and anti-sense strands. 565 
Following siRNAs were used for the experiments; HsBCAP siRNA1 566 
GCAAGAAGCAGCUGAAAUAUU (sense)/GCAAGAAGCAGCUGAAAUAUU 567 
(antisense) and HsBCAP siRNA2, GGAGAAGGCUGUAAAUGAUUU (sense)/ 568 
AUCAUUUACAGCCUUCUCCUU (antisense). The siRNA sequences targeting 569 
the two individual transcripts HsBCAPα siRNA 570 
UGAAGGAGUUAGAGCGUGUUU (sense) / ACACGCUCUAACUCCUUCAUU 571 
(antisense) and  HsBCAP δ siRNA AGUCUUGAGAAGUCGGAAAUU (sense)/  572 
UUUCCGACUUCUCAAGACUUU (antisense). A SMARTPool ON-TARGETplus 573 
siRNA to PCM-1 was purchased from Dharmacon. Oligos were resuspended 574 
in 200 µL of RNase-free water to make a stock solution of 100 µM and stored 575 
at -80°C. The working concentrations of 10 µM aliquots were also made by 576 
diluting 100 µM stock with RNase free water and stored in -80°C. For 577 
delivering siRNAs to mammalian cells, Lipofectamine RNAiMAX (Life 578 
Technologies) was used according to manufacturer’s protocol. For 579 
transfection of mammalian cell lines, 1x106 cells were plated per well of a 6-580 
well plate (reverse transfection).  All the transfection complexes were 581 
prepared in sterile 6-well plates and for each well, 2.5-3 µL of siRNA (from 582 
10 µM working concentration) and 7.5 µL of Lipofectamine RNAiMAX diluted 583 
in 500 µL of Opti-MEM and mixtures were incubated at room temperature 584 
for 10-15 min to allow the complexes to form. Then the cell suspension was 585 
added to each well containing siRNA-RNAiMAX complexes and diluted with 586 
culture medium without antibiotics to make a final volume of 2.5 mL per 587 
well. 588 
 589 
Cell extracts, SDS PAGE and Western blotting 590 
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 591 
Whole-cell extracts for Western blotting were prepared by washing 592 
cells in phosphate-buffered saline (PBS), followed by lysis in cell lysis buffer 593 
(50 mM Tris-HCL (pH 7.5), 150mM NaCl, 1 mM EDTA, 10% Glycerol, 1% 594 
Triton X-100) containing a protease inhibitor cocktail (P8340, Sigma-595 
Aldrich) at 4°C for 30 min. Then the cell debris was removed by centrifuging 596 
at 12000 xg at 4°C for 20 min. Prior to SDS-PAGE, protein concentration 597 
was determined using BioRad DC assay (BioRad, UK) according to the 598 
manufacturer’s instructions. Small 10% SDS polyacrylamide gels (8x6.5x 599 
cm) with 0.75mm thickness were hand cast using Biorad Mini-Protein II 600 
casting chamber. Approximately 5-15 µg of protein samples were prepared 601 
with 1x SDS-PAGE buffer and 1x reducing agent (Invitrogen), heat 602 
denatured for 10 min at 70°C and kept in ice until loaded. For running the 603 
gel, 20 µL of the protein sample alone with PageRuler Plus pre-stained 604 
protein ladder (ThermoFisher Scientific) were loaded in to each well and gels 605 
were run with SDS-PAGE running buffer (Sambrook and Russell, 2001) in a 606 
BioRad Mini Protein II gel chamber at 100 V for 1.5 h. The proteins 607 
separated from SDS-PAGE gel subsequently transferred on to activated 608 
PVDF-FL (Millipore) membrane with an aid of BioRad mini protein II wet 609 
blotting system filled with transfer buffer. Membranes were blocked with 610 
Odyssey blocking solution (Licor) or 1x Casein buffer (Sigma-Aldrich, 611 
B6429), and washed with Tris-buffered saline containing 0.5% Tween20 612 
(Sigma-Aldrich) and probed with primary antibodies. Bound primary 613 
antibodies were detected using secondary antibodies (anti-mouse IRDye 614 
680RD, 1:15000 and anti-rabbit IRDye 800CW, 1:15000) using Odyssey SA 615 
near infrared fluorescent (Licor) detector. The images were captured using 616 
Image studio software (Licor) version 3. 617 
 618 
Cells migration assay (Scratch-Wound Assay) 619 
 620 
To assess the cell migration pattern and polarity, a scratch-wound 621 
assay was performed on RPE1-hTERTcells. The cells were seeded on to a 622 
glass coverslip placed in a 6-well plate and grown in an incubator to reach 623 
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about 90% confluency. Then a linear scratch wound was made using a 624 
blunt sterile P200 tip between parallel edges of the coverslip as described in 625 
(Wells and Parsons, 2011; Nobes and Hall, 1999).  The coverslips were 626 
washed two times with PBS and incubated with fresh media for 24h until 627 
the wound was closed. The coverslips were fixed in cold methanol at 628 
different time points before processing for immunocytochemistry as above.  629 
 630 
Cell cycle synchronisation 631 
 632 
For cell synchronisation at G2/M transition phase, hTERT-RPE1 cells 633 
were seeded and cultured until 70-80% confluency followed by treatment 634 
with 1.5 µM nocodozole for 24h as described (Uetake and Sluder, 2007). To 635 
release from G2/M arrest, cells were washed twice with PBS and incubated 636 
in serum free growth media. Cells were fixed at various timepoints in 1% FA 637 
and stained with anti-γ-tubulin, anti-BCAP and anti-acetylated alpha 638 
tubulin primary antibodies as above.  639 
 640 
Cells cycle analysis using FACS 641 
 642 
For the FACS based cell cycle analysis, hTERT-RPE-1 cells were grown 643 
under normal culture conditions in a 6-well plate. Once the cells reached 644 
80-90% confluency, cells were trypsinised and harvested as described above 645 
and washed twice with PBS. The cells were then fixed in ice cold 70% 646 
ethanol for at least 30 min on ice and washed twice with PBS. Cells were 647 
treated with 100 µg/ml RNase A solution in PBS followed by 50 µg/ml 648 
propidium iodide (PI). Cells were stained overnight in a dark chamber at 649 
room temperature and data was collected using BD FACSCANTO I (BD 650 
Bioscience, Oxford, UK) flow cytometer set to collect in the linear scale. Cell 651 
cycle analysis was performed using BD FACSDiva (BD Bioscience) and 652 
FlowJo version X.  653 
 654 
Phylogenetic analysis 655 
 656 
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Data was aligned and trees were constructed in CLC genomics workbench 657 
v7.5, using the default settings for alignment (Gap open cost 10, Gap 658 
extension cost 1) and with trees estimated using Kimura protein distances, 659 
with neighbour joining.  660 
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Figure Legends 682 
 683 
Figure 1. Localisation of ODF2-like / BCAP. A-C) HeLa cells stained with 684 
anti-γ-tubulin (A, red), the anti-BCAP (Biorbyt) antibody (B, green) and DAPI 685 
(blue in combined image, C) showing a cloud of small spots clustered 686 
around the centrosome, 1-2 punctae of γ-tubulin. D-F) anti-BCAP staining 687 
(red, D) coincides with GFP-BCAP fluorescence (green, E), the overlaid 688 
signals shown in (F). G) GFP-BCAP (green) displays a punctate staining 689 
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around the centrosome, cells stained with anti-gamma tubulin (red), DAPI in 690 
blue.  H) HeLa cells stained with anti-PCM1 antibody (green) show a similar 691 
pattern of staining, characteristic of centriolar satellites. I) For BCAP (green), 692 
staining is around the centrosome but not on the centrioles: γ-tubulin (red) 693 
staining does not overlap with BCAP. This is a magnified portion of (C). J-L) 694 
PCM-1 staining (red, J) coincides with GFP-BCAP staining (green, K), the 695 
overlaid signals shown in (L). M) PCM1(green), γ-tubulin (red) are unaffected 696 
in control siRNA cells. N) PCM-1 (green) is depleted by RNAi using an siRNA 697 
targetted to PCM-1 (γ-tubulin in red). O) siRNA depletion of PCM-1 results in  698 
BCAP (green) no longer localising at the satellites. Instead a diffuse, non-699 
punctate cytoplasmic staining is observed. Scale bars 10 µm except (E), 2 700 
µm.  701 
 702 
Figure 2.  703 
A) Phylogenetic analysis of the relationship between BCAP and ODF2. 704 
Sequences used were from Xenopus tropicalis (Xt), Anolis carolinensis (Ac), 705 
Gallus gallus (Gg), Mus musculus (Mm) and Homo sapiens (Hs). The tree was 706 
constructed using CLC Genomics. Bootstrap support values are indicated 707 
above branches. B) Schematic of the BCAP gene and BCAP isoforms. The 708 
NCBI database and Ponsard et al. have predicted/observed several 709 
transcripts and isoforms. These are summarised here. We have named them 710 
α−η to combine while avoiding confusion. NCBI numbering (a-d) and 711 
Ponsard et al. naming schemes (S/L-BCAP del x) are also shown for 712 
completeness. In isoforms where exons are skipped, the number of the exon 713 
skipped is in the gap between the two exons that are incorporated. Single-714 
headed arrows show the binding sites for primers used to determine which 715 
variants were present. Target sites for the siRNAs used in this study are 716 
shown in red at the base of the diagram, lines with blunt arrowheads 717 
showing which isoforms would be targetted. The α and δ protein isoforms 718 
differ in the C-terminus, with BCAPα having a 50 amino acid insertion by 719 
inclusion of exon 13  compared to BCAPδ, which possesses an additional 20 720 
amino acids in the tail due to inclusion of exon 19 instead of exon 18. The 721 
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anti-BCAP (Biorbyt) antibody was raised to the C-terminus of BCAPα 722 
whereas the anti-BCAP (Proteintech) antibody binds the N-terminus of BCAP 723 
and so will detect both BCAPα and BCAPδ.  724 
 725 
Figure 3. BCAP and ciliogenesis. A) In proliferating RPE1-hTERT cells in 726 
serum-supplemented medium (SSM), endogenous BCAP (anti-BCAP 727 
(Biorbyt) antibody, green) localises in satellites around the centrosome (γ-728 
tubulin, red) next to the nucleus (DAPI, blue). B) In serum-free medium 729 
(SFM), cilia (acetylated tubulin, red) are formed and BCAP staining (green) 730 
disappears (DAPI in blue). C, D) When cells are transfected with a GFP-731 
BCAP expression plasmid (C, GFP only; D, GFP plus acetylated tubulin (red) 732 
and DAPI (blue)), untransfected cells (left-hand cell) form a cilium whereas 733 
transfected cells do not (right-hand cell). E) There is a 40% reduction in the 734 
number of cells with cilia when GFP-BCAP is expressed ( p<0.001 by 735 
Student’s t-test, 100 cells counted , n=3). G) Western blotting confirms that 736 
BCAP (green, running at nearly 70kDa), does not disperse, instead the 737 
protein disappears. This is quantified in (F). 738 
 739 
Figure 4. BCAP depletion promotes ciliogenesis. A, B) two different siRNA 740 
duplexes both effectively deplete BCAP: a 600 bp fragment of BCAP is 741 
amplified by RT-PCR in various control samples (untransfected, 742 
lipofectamine and non-target siRNA) but is absent when proliferating RPE1-743 
hTERT cells are treated with the siRNAs; beta actin is amplified to the same 744 
level in all samples (three independent experiments p<0.001 by one-way 745 
ANOVA). C) By immunofluorescence, BCAP signal disappears in siRNA-746 
treated cells (BCAP signal alone in green). D) γ-tubulin signal is unaffected 747 
by BCAP depletion (γ-tubulin in red, BCAP in green, plus DAPI in blue). E) A 748 
large portion of these cells in serum supplemented medium now form cilia 749 
(acetylated tubulin in red) F) Only 7% of control cells form cilia but 79% of 750 
cells treated with siRNAs ciliate, total of 100 cells counted, p<0.001 by chi-751 
squared. This is data from one experiment; three repeats show similar 752 
results. G-I) Cilium length also increases in serum-starved and BCAP-753 
depleted RPE1-hTERT cells  from 3 µm to 4 µm, p<0.001 by Student’s t-test, 754 
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150 cilia counted in each sample. (J). Examples of control cilia are shown in 755 
(G), long cilia observed after siRNA treatement shown in (H) and (I). K-N) 756 
Mouse BCAP will rescue RNAi-depletion, with transfected cells not making 757 
cilia, shown separately in (L) and with DAPI and GFP-BCAP together in (M) 758 
(p<0.001 by Student’s t-test, 100 cells counted in three separate repeats) . 759 
BCAP staining is much reduced in BCAP siRNA treated cells (O-Q). However, 760 
γ-tubulin (P) and PCM-1 (Q) staining are unaffected.  761 
 762 
Figure 5. BCAP consists of at least two isoforms. A-C) in proliferating 763 
RPE1-hTERT cells in serum supplemented medium (SSM), the anti-BCAP 764 
(Proteintech) antibody (green) shows satellite staining around the 765 
centrosomes (γ-tubulin, red).  D,E) in contrast to the Western blot using the 766 
Biorbyt antibody as probe, when the anti-BCAP (Proteintech) antibody 767 
(green) is used to probe cell extracts before and after ciliogenesis, levels of 768 
this protein decrease slightly rather than disappear. Beta actin is stained in 769 
red. F-H) In serum free medium (SFM), cells at presumably different stages 770 
of ciliogenesis can be observed. BCAP can be observed at the base of the 771 
cilium or clustered away from it. I) The anti-BCAP (Proteintech) antibody 772 
staining (green) colocalises with that of PCM-1 (red). J) Satellite-like staining 773 
of BCAP from the anti-BCAP (Proteintech) antibody (green) but with some 774 
overlap with the γ-tubulin signal (red). K) As expected, ODF2 (red) shows a 775 
single punctum of signal (the mother centriole) in contrast to the staining 776 
from the anti-BCAP (Proteintech) antibody (green). Scale bar, 10 µm. 777 
 778 
Figure 6. BCAP levels and localisation change during ciliogenesis. 779 
RPE1-hTERT cells were synchronised by a nocodazole block followed by 780 
release. Samples were fixed at hourly intervals, with timepoints at which key 781 
changes took place shown here. After release at 1h, BCAP (green) is 782 
dispersed in the cytoplasm, as is the γ-tubulin signal (red). While the γ-783 
tubulin signal reorganises into recognisable centrosomes between 2-4h, 784 
BCAP signal disappears. At 6h, cilia are visible and BCAP signal is 785 
returning. By 8h, ciliogenesis appears complete and strong BCAP signal is 786 
visible at the base of cilia. Cells were also stained with DAPI (blue). The right 787 
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hand column summarises these changes, with satellites/BCAP as small 788 
green dots, the centrioles/basal body/cilium in red and nucleus in blue. B) 789 
Signal intensity of BCAP was measured at each stage. BCAP is highly 790 
expressed at the first time-point and then gradually decreases. By 8 hours 791 
its expression has increased again to 50% of its pre-ciliation value. C) 792 
Number of cilia at each time point was measured, with 60% of cells showing 793 
cilia by 8h. This represents three independent experiments. Scale bar, 10 794 
µm. 795 
 796 
Figure 7 BCAP exists as multiple isofroms, two are present in RPE1-797 
hTERT cells. A) RT-PCR using primers to amplify exons 9-11 yields one 798 
smaller band corresponding to skipping of exon 10. RT-PCR with primers to 799 
amplify exons 12-15 yields two bands corresponding to inclusion or 800 
skipping of exon 13. B) Full-length BCAPα and δ are present in RPE1-hTERT 801 
cells. There is only one band for BCAPδ but the primers would also amplify 802 
the shorter BCAPε were it to be present. C-E) GFP-BCAPα shows a satellite-803 
like staining that colocalises with that of PCM-1 (red). F-H) This GFP-BCAPα 804 
signal is around but not overlapping γ-tubulin (red). I-K) GFP-BCAPα forms 805 
a cloud of punctae around the single ODF2 punctum (red). L-N) GFP-BCAPδ 806 
shows a pericentriolar/centriolar-like staining, overlapping γ-tubulin in 807 
about 80% of cells. O-Q) GFP-BCAPδ shows a satellite-like staining 808 
overlapping PCM-1 (red) in about 20% of cells.  809 
 810 
Figure 8 BCAPα and δ have overlapping but subtly distinct roles in 811 
ciliogenesis. A-B) BCAPα and BCAPδ were depleted individually by siRNA. 812 
The amount of depletion of each isoform was assessed quantitatively by RT-813 
PCR ( p<0.001 by one-way ANOVA, three repeats). C-E) Depletion of either 814 
BCAPα or δ individually reduces but does not eliminate the Proteintech 815 
antibody staining (green) which binds both isoforms. γ-tubulin staining (red) 816 
shows the centrioles and pericentriolar matrix are grossly intact. F) 817 
Depletion of either isoform, BCAPα or δ, individually causes cells to form 818 
cilia in serum supplemented conditions (p<0.001 by one-way ANOVA, 100 819 
27 
 
cells counted in three repeats). G-I) In BCAPδ− but not BCAPα− depleted 820 
cells longer cilia are observed, quantified in (J) (p<0.001 by one-way ANOVA, 821 
100 cells counted in three repeats). K-P) Expressing either GFP-BCAPα or δ 822 
in serum-free conditions suppresses normal ciliation. Left hand cell is 823 
untransfected, right hand cell is transfected. Cilia labelled with anti-824 
acetylated tubulin (red). This is quantified in (Q) (p<0.001 by one-way 825 
ANOVA, 100 cells counted in three repeats). R-X) GFP-BCAPα can rescue 826 
BCAPδ-siRNA, with cells not making cilia in serum-supplemented conditions 827 
(cilia/acetylated tubulin in red). The same is true for the reciprocal 828 
experiment. This is quantified in (X) (p<0.001 by one-way ANOVA, 100 cells 829 
counted in three repeats).  830 
 831 
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